May 24th, 2022 (Earnings Report)Dear Reader,Our scanners just identified several healthtech stocks that are expected to release earnings starting today, January 26th.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
CVRx
Symbol: CVRX
Recent Price: $14.56
Average Analyst Price Target: $17.83 (22.46%)
Market Cap: $307.32M
Last Year's EPS: -$0.52
Consensus EPS Forecast: -$0.56
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Alexander Nowak, analyst at Craig-Hallum, reiterates coverage on CVRx (CVRX) in the Healthcare sector with a Buy rating and a price target of $ 18 (2 weeks ago).
TipRanks.com also reports that CVRx currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.83 . The target pricing ranges from a high forecast of $18.50 down to a low forecast of $17.00. CVRx (CVRX)’s last closing price was $14.56 which would put the average price target at 22.46% upside.Here are 3rd party ratings for CVRX:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 37% (93 out of 251)
--------------------------------------------------------------------------
Meridian Bioscience
Symbol: VIVO
Recent Price: $33.76
Average Analyst Price Target: $34.00 (0.71%)
Market Cap: $1.48B
Last Year's EPS: $0.35
Consensus EPS Forecast: $0.2
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on Meridian Bioscience (VIVO) in the Healthcare sector with a Hold rating and a price target of $ 34 (1 month ago).
TipRanks.com also reports that Meridian Bioscience currently has 1 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $34.00 . The target pricing ranges from a high forecast of $34.00 down to a low forecast of $34.00. Meridian Bioscience (VIVO)’s last closing price was $33.76 which would put the average price target at 0.71% upside.Here are 3rd party ratings for VIVO:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 41% (102 out of 251)
--------------------------------------------------------------------------
Quipt Home Medical
Symbol: QIPT
Recent Price: $6.07
Average Analyst Price Target: $9.29 (52.83%)
Market Cap: $213.82M
Last Year's EPS: -$0.04
Consensus EPS Forecast: -$0.02
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Stefan Quenneville, analyst at Echelon Wealth Partners, reiterates coverage on Quipt Home Medical (QIPT) in the Healthcare sector with a Buy rating and a price target of $ 8.79 (2 weeks ago).
TipRanks.com also reports that Quipt Home Medical currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.29 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $8.80. Quipt Home Medical (QIPT)’s last closing price was $6.07 which would put the average price target at 52.83% upside.Here are 3rd party ratings for QIPT:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 41% (102 out of 251)
--------------------------------------------------------------------------
Resmed
Symbol: RMD
Recent Price: $233.62
Average Analyst Price Target: $259.67 (11.15%)
Market Cap: $34.38B
Last Year's EPS: $1.47
Consensus EPS Forecast: $1.6
Expected Earnings Date: Jan 25 2023
Recent Analyst Action: Michael Matson, analyst at Needham, reiterates coverage on Resmed (RMD) in the Healthcare sector with a Hold rating and has not provided a price target (5 days ago).
TipRanks.com also reports that Resmed currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $259.67 . The target pricing ranges from a high forecast of $280.00 down to a low forecast of $245.00. Resmed (RMD)’s last closing price was $233.62 which would put the average price target at 11.15% upside.Here are 3rd party ratings for RMD:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 41% (102 out of 251)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
